Comprehensive Pneumology Center, Institute of Lung Biology and Disease, Helmholtz Zentrum München and University Hospital of the Ludwig-Maximilians University, Munich, Germany.
INSERM U-1100, "Centre d'Etude des Pathologies Respiratoires" and Université François Rabelais, Tours, France.
J Heart Lung Transplant. 2018 Aug;37(8):1021-1028. doi: 10.1016/j.healun.2018.03.015. Epub 2018 Mar 30.
Vascular damage and primary graft dysfunction increase with prolonged preservation times of transplanted donor lungs. Hence, storage and conservation of donated lungs in protein-free, dextran-containing electrolyte solutions, like Perfadex, is limited to about 6 hours. We hypothesized that transplanted lungs are protected against neutrophil-mediated proteolytic damage by adding α-anti-trypsin (AAT), a highly abundant human plasma proteinase inhibitor, to Perfadex.
A realistic clinically oriented murine model of lung transplantation was used to simulate the ischemia-reperfusion process. Lung grafts were stored at 4°C in Perfadex solution supplemented with AAT or an AAT mutant devoid of elastase-inhibiting activity for 18 hours. We examined wild-type and proteinase 3/neutrophil elastase (PR3/NE) double-deficient mice as graft recipients. Gas exchange function and infiltrating neutrophils of the transplanted lung, as well as protein content and neutrophil numbers in the bronchoalveolar lavage fluid, were determined.
AAT as a supplement to Perfadex reduced the extent of primary graft dysfunction and early neutrophil responses after extended storage for 18 hours at 4°C and 4-hour reperfusion in the recipients. Double-knockout recipients that lack elastase-like activities in neutrophils were also protected from early reperfusion injury, but not lung grafts that were perfused with a reactive center mutant of AAT devoid of elastase-inhibiting activity.
PR3 and NE, the principal targets of AAT, are major triggers of post-ischemic reperfusion damage. Their effective inhibition in the graft and recipient is a promising strategy for organ usage after storage for >6 hours.
移植供体肺的血管损伤和原发性移植物功能障碍随着保存时间的延长而增加。因此,在无蛋白、含右旋糖酐的电解质溶液(如 Perfadex)中储存和保存捐献的肺,时间限制在大约 6 小时内。我们假设通过在 Perfadex 中添加α-抗胰蛋白酶(AAT),一种丰富的人血浆蛋白酶抑制剂,可以保护移植肺免受中性粒细胞介导的蛋白水解损伤。
使用现实的、临床导向的鼠肺移植模型模拟缺血再灌注过程。肺移植物在 4°C 的 Perfadex 溶液中保存,补充 AAT 或缺乏弹性蛋白酶抑制活性的 AAT 突变体 18 小时。我们检查了野生型和蛋白酶 3/中性粒细胞弹性蛋白酶(PR3/NE)双缺失小鼠作为移植物受体。测定移植肺的气体交换功能和浸润的中性粒细胞,以及支气管肺泡灌洗液中的蛋白含量和中性粒细胞数。
AAT 作为 Perfadex 的补充剂,可减少在 4°C 下延长 18 小时储存和 4 小时再灌注后原发性移植物功能障碍和早期中性粒细胞反应的程度。缺乏中性粒细胞弹性酶样活性的双敲除受体也能免受早期再灌注损伤的影响,但缺乏弹性蛋白酶抑制活性的 AAT 活性中心突变体灌注的肺移植物不受影响。
PR3 和 NE 是 AAT 的主要靶标,是缺血后再灌注损伤的主要触发因素。在移植物和受体中有效抑制它们是储存时间超过 6 小时后器官使用的有前途的策略。